Saba is a private investor in public and private equities, focusing on biopharma companies. He is an angel investor and advisor to medical device and mobile health/HCIT startups, with a successful exit under his belt. He recently assumed the CEO role at CytImmune, a Ph2-ready oncology biotech.
Saba was previously a Managing Director with Putnam Investments where he focused on investments in technology. Previously, he was a Principal with the Boston Consulting Group (BCG) where he focused on healthcare and telecoms.
He studied engineering at Tufts and Penn, and has an MBA from Harvard Business School.
Saba is attending / has attended: